Page 82 - Abt News Today

Abbott Laboratories (NYSE:ABT – Get Free Report) had its target price cut by research analysts at UBS Group from $130.00 to $118.00 in a report released on Thursday. UBS Group’s price target would indicate a potential upside of 25.48% from the stock’s previous close. A number of other equities research analysts have also recently weighed […]

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

Strong medical device sales boost results even as investors fear obesity drugs' impact.

Crossmark Global Holdings Inc. decreased its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 32.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 191,965 shares of the healthcare product maker’s stock after selling 93,543 shares during […]

Ramsay Stattman Vela & Price Inc. cut its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 112,653 shares of the healthcare product maker’s stock after selling 684 shares during the period. […]

By Dean Seal Abbott Labs reported roughly flat earnings and lower sales in the third quarter. Here's what you need to know. PROFIT: The Abbott Park,...

Abbott Laboratories (NYSE:ABT – Get Free Report)’s stock price gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $92.14, but opened at $96.00. Abbott Laboratories shares last traded at $94.86, with a volume of 2,625,322 shares trading hands. The healthcare product maker reported $1.14 […]

Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance...

Abbott Laboratories (NYSE:ABT – Get Free Report) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $4.42-$4.46 for the period, compared to the consensus estimate of $4.18. The company issued revenue guidance of -. Abbott Laboratories also updated its FY23 guidance to $4.42-4.46 […]

Courier Capital LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 9.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,647 shares of the healthcare product maker’s stock after selling 2,227 shares during the period. Courier […]